Navigation Links
Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
Date:3/17/2010

SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen.  ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.  Hydrocodone is the most widely prescribed drug in the United States, but there are currently no products available with hydrocodone only, or with controlled-release formulations.  ZX002, which incorporates Elan's proprietary SODAS® technology, offers a unique controlled-release profile which utilizes both immediate release and extended release properties designed to enable twice daily dosing.

"We are pleased to be initiating this pivotal Phase 3 trial of ZX002 as the first single-entity, controlled-release hydrocodone formulation," said Cynthia Robinson, Ph.D., chief development officer of Zogenix.  "We believe this hydrocodone therapy could offer significant benefits to both the patient and the practicing physician by allowing for less frequent dosing with a customized controlled-release profile and the ability to titrate to higher hydrocodone doses than currently recommended for hydrocodone products burdened by combination formulations. Further, we believe ZX002 may offer patients an option for the treatment of their chronic pain that potentially avoids some of the serious side effects that can accompany chronic use of combination opioids that contain acetaminophen, or other n
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
2. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
3. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
4. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
5. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
6. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
7. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
8. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
11. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... targeting specific pathogens that cause serious infections and diseases, ... activity in the Company,s stock, the NYSE MKT (the ... usual practice. The Company stated that its policy is ... About Synthetic Biologics, Inc. Synthetic Biologics, Inc. ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... , MINNETONKA, Minn., Dec. 1 ... company specializing in clinical study management systems, today ... technology solution, has been certified by the Clinical ... the Operational Data Model (ODM) standard. This ...
... , CAMBRIDGE, Mass. and TOKYO, Dec. 1 Galenea ... further extension of their research and development collaboration through ... to seven years and brings the total committed funding ... working together since January 2005 with the goal of ...
Cached Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... adult autism patients with just a single dose of the ... and emotions, Japanese researchers report. Known as the "love ... emotional bonding between lovers, and between mothers and their children. ... a key area of the brain that has long been ...
(Date:7/29/2014)... 29, 2014 Summer is here, and that means ... a hike, swimming in a pool or laying out on the ... and ticks. The Puppy Store is here to help pet owners ... , It’s almost impossible to completely keep fleas and ticks at ... the chances of their pets coming into contact with fleas and ...
(Date:7/29/2014)... Bret Busacker , a partner ... has been appointed to the Board of Directors for ... is an experienced business attorney with a focus on ... on a wide spectrum of topics regarding equity and ... governance concerns. His clients include public and private businesses, ...
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market by ... Fluids, & Others), by Application (Oil & Gas, Chemical, ... Trends & Forecasts to 2019” defines and segments the ... forecast of the global consumption in terms of volume ... figures spread through 199 page sand in-depth TOC on"Heat ...
(Date:7/29/2014)... (HealthDay News) -- Quitting smoking is harder for people with ... can make it more difficult to ride out the anxiety, ... quit cold turkey, scientists found. But extra exercise -- even ... said. "The review should be seen as a call ... in the department of exercise science at Concordia University in ...
Breaking Medicine News(10 mins):Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News: Extra Exercise Could Help Depressed Smokers Quit: Study 2
... grains and cereals and of magnesium may each be associated ... a report and meta-analysis in the issue of Archives ... of people diagnosed with diabetes worldwide may increase from 171 ... background information in the article. The associated illness, death and ...
... Those men who are facing the surgical removal of ... day will come when they need not worry ... a team of expert urologic surgeons at NewYork-Presbyterian Hospital/Weill ... of reconstructing key anatomical structures that ensure continence. ...
... Maine in Portland have revealed that Depleted Uranium (DU) weapons ... has been denying the possibility. ,Previous research at ... that people exposed to DU dust were at little extra ... inadequately radioactive metal that is used in armour-piercing shells and ...
... shown that subtle signs may enable early prediction of Huntingtons ... and some aspects of personality. ,Dr. Jane ... Lucille A. Carver College of Medicine in Iowa City studied ... ,Each of the participants had at least one parent who ...
... bad tidings for those heavy-handed on multivitamins. The research conducted ... who take more than seven multivitamin tablets a week, can ... type of prostate cancer. ,The researchers who ... Cancer Institute, followed 295,344 men who reported ...
... day could help improve fitness and health of women who ... ,Conducting tests on overweight and obese women, many of whom ... Rouge found that even ten minutes of exercise a day ... their overall risk of early death. ,The study ...
Cached Medicine News:Health News:Risk of Diabetes is Reduced by Intake of Grain Fiber and Magnesium 2Health News:Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy 2Health News:Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy 3Health News:Early Prediction of Huntingtons Disease is Possible by Subtle Signs 2Health News:Being Overzealous With Multivitamins May Lead To Prostate Cancer 2
... Steri-Cath™ Closed Ventilation Suction Systems Reduce ... Constant Patient Ventilation, ,Cost-effective and ... Ventilation Suction Systems reduces the risk ... contact with the catheter, Steri-Cath™ maintains ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
... Our Tri-Flo® suction catheter design ... to your patients while still providing ... pediatric catheters (5/6, 8 or 10 ... facilitate proper catheter placement. Our complete ...
Medicine Products: